BioTissue announced an update to CAM360 AmnioGraft (CAM360 AG), its cryopreserved amniotic membrane (CAM) therapy for mild to moderate ocular surface disease. The new dual-tab design was developed to facilitate handling and preparation for eyecare professionals (ECPs).
Introduced in 2024, CAM360 AG featured a ringless, hydrated and shelf-stable design that eliminated the need for refrigeration while delivering a treatment experience designed for comfort. Like the original CAM360 AG, the updated design leverages BioTissue’s proprietary cryopreservation technology to preserve the key biological properties of amniotic membrane. CAM technology may be used across a range of ocular surface conditions, including dry eye disease, superficial punctate keratitis and neurotrophic keratitis.


